NCT02857270 2022-11-22A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic CancerEli Lilly and CompanyPhase 1 Completed210 enrolled
NCT04165031 2021-11-24A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C MutationEli Lilly and CompanyPhase 1/2 Terminated5 enrolled 9 charts